All In Biotech

Drug Trial Radar · NCT02892344

Study of QMF149 (150/80 µg) Compared With MF Twisthaler® (200 µg) in Patients With Asthma

A Multi-center, Randomized, 12-week Treatment, Doubleblind Study to Assess the Efficacy and Safety of QMF149 (150/80 Microgram) Compared With MF Twisthaler® (200 Microgram) in Adult and Adolescent Patients With Asthma

Last checked: Nov 19, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 802 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

802

Actual

Start

Jan 16, 2017

Primary completion

Nov 5, 2018

Study completion Nov 30, 2018

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Sep 8, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the trial was to evaluate efficacy and safety of QMF149 150/80 microgram o.d. delivered via Concept1 compared to MF 200 microgram o.d., delivered via Twisthaler® in terms of lung function and symptom control in poorly (ie inadequately) controlled asthma patients. This study was to assess contribution of LABA as an add-on therapy to low dose ICS monotherapy.

Conditions

  • Mild Asthma

Interventions

  • QMF149 150/80 μgDrug

    QMF149 150/80 μg o.d via Concept1

  • MF 200 μgDrug

    MF 200 μg o.d. via Twisthaler®

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Trough FEV1Time frame: week 12

Locations

123 sites in 22 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Pleven, Bulgaria

  • Novartis Investigative Site

    Bulgaria, Bulgaria, Bulgaria

  • Novartis Investigative Site

    Stara Zagora, Bulgaria, Bulgaria

  • Novartis Investigative Site

    Santiago, Chile

  • Novartis Investigative Site

    Santiago, Chile

  • Novartis Investigative Site

    Viña del Mar, Chile

  • Novartis Investigative Site

    Santiago, Santiago Metropolitan, Chile

  • Novartis Investigative Site

    Bogotá, Colombia

  • Novartis Investigative Site

    Medellín, Antioquia, Colombia

  • Novartis Investigative Site

    Bucaramanga, Colombia, Colombia

  • Novartis Investigative Site

    Medellín, Colombia, Colombia

  • Novartis Investigative Site

    Bogota, Cundinamarca, Colombia

  • Novartis Investigative Site

    Kohtla-Järve, Estonia

  • Novartis Investigative Site

    Tallinn, Estonia

  • Novartis Investigative Site

    Tartu, Estonia

  • Novartis Investigative Site

    Tartu, Estonia, Estonia

  • Novartis Investigative Site

    Bad Wörishofen, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Darmstadt, Germany

  • Novartis Investigative Site

    Frankfurt, Germany

  • Novartis Investigative Site

    Gauting, Germany

  • Novartis Investigative Site

    Hamburg, Germany

  • Novartis Investigative Site

    Hanover, Germany

  • Novartis Investigative Site

    Landsberg, Germany

  • Novartis Investigative Site

    Leipzig, Germany

  • Novartis Investigative Site

    Lübeck, Germany

  • Novartis Investigative Site

    Mainz, Germany

  • Novartis Investigative Site

    Bochum, Germany, Germany

  • Novartis Investigative Site

    Marburg, Germany, Germany

  • Novartis Investigative Site

    Cegléd, Hungary

  • Novartis Investigative Site

    Gödöllő, Hungary

  • Novartis Investigative Site

    Győr, HUN, Hungary

  • Novartis Investigative Site

    Százhalombatta, HUN, Hungary

  • Novartis Investigative Site

    Szarvas, Hungary, Hungary

  • Novartis Investigative Site

    Szeged, Hungary, Hungary

  • Novartis Investigative Site

    Törökbálint, Pest County, Hungary

  • Novartis Investigative Site

    Ahmedabad, Gujarat, India

  • Novartis Investigative Site

    Vadodara, Gujarat, India

  • Novartis Investigative Site

    Bangalore, Karnataka, India

  • Novartis Investigative Site

    Hubli, Karnataka, India

Showing 40 of 123 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.